NEUVOGEN has developed a best-in-class therapeutic cancer vaccine platform with broad potential across a range of solid tumors.
Our pipeline is focused on generating off-the-shelf therapies designed to eliminate primary tumors, micro-metastases, and clinical metastases in solid tumor indications.
Each NEUVOGEN product candidate is engineered to harness and activate the patient’s own immune system, offering enhanced efficacy while maintaining a strong safety profile—all at a lower cost of goods compared to other cancer vaccine approaches.
Pipeline Overview
| Product | Indication |
| NGEN-143 | Non-Small Cell Lung Cancer (NSCLC) |
| NGEN-241 | Prostate Cancer |
| NGEN-121 | Colorectal Cancer |
| NGEN-221 | Breast Cancer |
| NGEN-181 | Head & Neck Cancer |
| NGEN-281 | Glioblastoma (GBM) |
| NGEN-261 | Bladder Cancer |
| NGEN-122 | Gastric Cancer |
| NGEN-242 | Ovarian Cancer |
| NGEN-123 | Pancreatic Cancer |
Lead Program: NGEN-143
NGEN-143 is NEUVOGEN’s lead product candidate, developed as an off-the-shelf therapeutic vaccine for NSCLC. The product comprises six genetically modified allogeneic tumor cell lines, each enhanced with NEUVOGEN’s proprietary activation technology to broaden tumor antigen presentation and improve immune engagement.
Extensive preclinical data—both in vitro and in vivo—support the advancement of NGEN-143 into clinical development.
For more information about our Science.